{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:12:22Z","timestamp":1790946742147,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40264-025-01612-y","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T17:51:16Z","timestamp":1757526676000},"page":"325-335","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Drugs Withdrawn from the Canadian Market for Safety and Effectiveness Reasons, 1990\u20132024: A Cross-Sectional Study"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5120-8029","authenticated-orcid":false,"given":"Joel","family":"Lexchin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"issue":"15","key":"1612_CR1","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1056\/NEJMp2209043","volume":"387","author":"T Hwang","year":"2022","unstructured":"Hwang T, Brawley O. New federal incentives for diversity in clinical trials. N Engl J Med. 2022;387(15):1347\u20139.","journal-title":"N Engl J Med"},{"issue":"9453","key":"1612_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","volume":"365","author":"P Rothwell","year":"2005","unstructured":"Rothwell P. External validity of randomised controlled trials: \u201cTo whom do the results of this trial apply?\u201d Lancet. 2005;365(9453):82\u201393.","journal-title":"Lancet"},{"issue":"1","key":"1612_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/ebmed-2017-110885","volume":"23","author":"I Onakpoya","year":"2018","unstructured":"Onakpoya I. Rare adverse events in clinical trials: understanding the rule of three. BMJ Evid Based Med. 2018;23(1):6.","journal-title":"BMJ Evid Based Med."},{"key":"1612_CR4","doi-asserted-by":"publisher","first-page":"1299239","DOI":"10.3389\/fmed.2023.1299239","volume":"10","author":"J Lexchin","year":"2023","unstructured":"Lexchin J. Quality and quantity of data used by Health Canada in approving new drugs. Front Med. 2023;10:1299239.","journal-title":"Front Med"},{"issue":"6","key":"1612_CR5","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1503\/cmaj.045021","volume":"172","author":"J Lexchin","year":"2005","unstructured":"Lexchin J. Drug withdrawals from the Canadian market for safety reasons, 1963\u20132004. CMAJ. 2005;172(6):765\u20137.","journal-title":"CMAJ"},{"issue":"1","key":"1612_CR6","first-page":"e14","volume":"8","author":"J Lexchin","year":"2014","unstructured":"Lexchin J. How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009. Open Med. 2014;8(1):e14\u20139.","journal-title":"Open Med"},{"key":"1612_CR7","unstructured":"Government of Canada. Drug and health product submissions under review (SUR): new drug submissions completed. 2025. https:\/\/www.canada.ca\/en\/health-canada\/services\/drug-health-product-review-approval\/submissions-under-review\/new-drug-submissions-completed.html."},{"issue":"10","key":"1612_CR8","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1345\/aph.1D110","volume":"37","author":"N Rawson","year":"2003","unstructured":"Rawson N, Kaitin K. Canadian and US drug approval times and safety considerations. Ann Pharmacother. 2003;37(10):1403\u20138.","journal-title":"Ann Pharmacother"},{"key":"1612_CR9","unstructured":"Withdrawn 2.0. 2023. https:\/\/bioinformatics.charite.de\/withdrawn_3\/index.php."},{"key":"1612_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2020.113005","volume":"255","author":"J Abraham","year":"2022","unstructured":"Abraham J, Davis C. International and temporal comparative analysis of UK and US drug safety regulation in changing political contexts. Soc Sci Med. 2022;255:113005.","journal-title":"Soc Sci Med"},{"key":"1612_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-019759","volume":"8","author":"S Lane","year":"2018","unstructured":"Lane S, Lynn E, Shakir S. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012. BMJ Open. 2018;8:e019759.","journal-title":"BMJ Open"},{"key":"1612_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004221","volume":"4","author":"R McNaughton","year":"2014","unstructured":"McNaughton R, Huet G, Shakir S. An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decisionmaking. BMJ Open. 2014;4:e004221.","journal-title":"BMJ Open"},{"issue":"3","key":"1612_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.24926\/iip.v3i3.269","volume":"3","author":"B Ninan","year":"2012","unstructured":"Ninan B, Wertheimer A. Withdrawing drugs in the U.S. versus other countries. Innov Pharm. 2012;3(3):1\u201312.","journal-title":"Innov Pharm."},{"key":"1612_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12916-016-0553-2","volume":"14","author":"I Onakpoya","year":"2016","unstructured":"Onakpoya I, Heneghan C, Aronson J. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016;14:10.","journal-title":"BMC Med"},{"issue":"5","key":"1612_CR15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s40264-017-0515-4","volume":"40","author":"I Onakpoya","year":"2017","unstructured":"Onakpoya I, Heneghan C, Aronson J. Post-marketing regulation of medicines withdrawn from the market because of drug-attributed deaths: an analysis of justification. Drug Saf. 2017;40(5):431\u201341.","journal-title":"Drug Saf"},{"key":"1612_CR16","unstructured":"Government of Canada. Notice of Compliance Search. 2025. https:\/\/health-products.canada.ca\/noc-ac\/?lang=eng."},{"key":"1612_CR17","unstructured":"Government of Canada. Drug Product Database online query. 2025. https:\/\/health-products.canada.ca\/dpd-bdpp\/."},{"issue":"2","key":"1612_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1046\/j.1365-2125.1998.00651.x","volume":"45","author":"D Jefferys","year":"1998","unstructured":"Jefferys D, Leakey D, Lewis J, Payne S, Rawlins M. New active substances authorized in the United Kingdom between 1972 and 1994. Br J Clin Pharmacol. 1998;45(2):151\u20136.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"1612_CR19","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/pds.2155","volume":"20","author":"Z Qureshi","year":"2011","unstructured":"Qureshi Z, Seoane-Vazquez E, Rodriguez-Monguiro R, Stevenson K, Szeinbach S. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiol Drug Safe. 2011;20(7):772\u20137.","journal-title":"Pharmacoepidemiol Drug Safe."},{"key":"1612_CR20","unstructured":"Government of Canada. Recalls and safety alerts. 2025. https:\/\/recalls-rappels.canada.ca\/en\/search\/site."},{"issue":"21","key":"1612_CR21","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1001\/archinternmed.2012.4444","volume":"172","author":"J Lexchin","year":"2012","unstructured":"Lexchin J. New drugs and safety: what happened to New Active Substances approved in Canada between 1995 and 2010? Arch Intern Med. 2012;172(21):1680\u20131.","journal-title":"Arch Intern Med"},{"issue":"5","key":"1612_CR22","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/bcp.12552","volume":"79","author":"J Lexchin","year":"2014","unstructured":"Lexchin J. Post-market safety warnings for drugs approved in Canada under the Notice of Compliance with conditions policy. Br J Clin Pharmacol. 2014;79(5):847\u201359.","journal-title":"Br J Clin Pharmacol"},{"key":"1612_CR23","unstructured":"Health Canada. Health Product Highlights Ottawa. 2021. https:\/\/www.canada.ca\/content\/dam\/hc-sc\/documents\/services\/publications\/drugs-health-products\/health-product-highlights-2021\/health-product-highlights-2021-en.pdf."},{"key":"1612_CR24","unstructured":"US Department of Health & Human Services. Search orphan drug designations and approvals. Silver Spring, MD: U.S. Food and Drug Administration; 2025 https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/listResult.cfm."},{"key":"1612_CR25","unstructured":"Government of Canada. Drug and health product portal: review decisions. 2025 https:\/\/dhpp.hpfb-dgpsa.ca\/review-documents?search=&f%5B0%5D=content_type%3Asbd."},{"key":"1612_CR26","unstructured":"Equator Network. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. 2023 [updated March 6]. https:\/\/www.equator-network.org\/reporting-guidelines\/strobe\/."},{"issue":"9","key":"1612_CR27","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1503\/cmaj.1041606","volume":"171","author":"B Sibbald","year":"2004","unstructured":"Sibbald B. Rofecoxib (Vioxx) voluntarily withdrawn from market. CMAJ. 2004;171(9):1027\u20138.","journal-title":"CMAJ"},{"issue":"5","key":"1612_CR28","first-page":"632","volume":"165","author":"E Wooltorton","year":"2001","unstructured":"Wooltorton E. Bayer pulls cerivastatin (Baycol) from market. CMAJ. 2001;165(5):632.","journal-title":"CMAJ"},{"key":"1612_CR29","doi-asserted-by":"crossref","unstructured":"Lexchin J. Orphan drug approval in Canada, 1999\u20132022: a cross-sectional study. Int J Health Policy Manag. 2025 (in press).","DOI":"10.34172\/ijhpm.8916"},{"issue":"17","key":"1612_CR30","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1001\/jama.287.17.2215","volume":"287","author":"K Lasser","year":"2002","unstructured":"Lasser K, Allen P, Woolhandler S, Himmelstein D, Wolfe S, Bor D. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287(17):2215\u201320.","journal-title":"JAMA"},{"issue":"3","key":"1612_CR31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2174\/157488607781668855","volume":"2","author":"A Issa","year":"2007","unstructured":"Issa A, Phillips K, Van Bebber S, Nidamarthy H, Lasser K, Haas J, et al. Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends. Curr Drug Safe. 2007;2(3):177\u201385.","journal-title":"Curr Drug Safe."},{"issue":"3","key":"1612_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.2026","volume":"8","author":"A Tibau","year":"2025","unstructured":"Tibau A, Hwang T, Romano A, Borrell M, Gich I, Molto C, et al. Factors in time to full approval or withdrawal for anticancer medicines granted accelerated approval by the FDA. JAMA Netw Open. 2025;8(3):e252026.","journal-title":"JAMA Netw Open"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01612-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-025-01612-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01612-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T10:00:19Z","timestamp":1771668019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-025-01612-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1612"],"URL":"https:\/\/doi.org\/10.1007\/s40264-025-01612-y","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"assertion":[{"value":"9 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Table 4, under the heading \"YE Mar 31, 2024\", the text is aligned in the original publication.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Joel Lexchin conceived of the idea for this study, gathered and analyzed all the information, wrote and revised the manuscript, and read and approved the final version.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Between 2022 and 2025, Joel Lexchin received payments for writing a brief for a legal firm on the role of promotion in generating prescriptions\u00a0for opioids, for being on a panel about pharmacare, and for co-writing an article for a peer-reviewed medical journal. He is a member of the Boards of Canadian Doctors for Medicare and the Canadian Health Coalition. He receives royalties from University of Toronto Press and James Lorimer & Co. Ltd. for books he has written. He has received funding from the Canadian Institutes of Health Research in the past.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All data were publicly available, and ethics approval was not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All the raw data collected for this study are available in File 1 in the ESM.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}